Table II.
Pharmacotherapy at Baseline
| demography | no. available/no. of total patients | %at baseline |
|---|---|---|
| Irbesartan alone or in fixed‐dose combination | ||
| Irbesartan 75 mg | 108/2173 | 5.0 |
| Irbesartan 150 mg | 709/2173 | 32.6 |
| Irbesartan 300 mg | 459/2173 | 21.1 |
| Irbesartan 150 mg/ HCTZ 12.5 mg | 298/2173 | 13.7 |
| Irbesartan 300 mg/ HCTZ 12.5 mg | 594/2173 | 27.3 |
| Further antihypertensive pharmacotherapy | ||
| None | 629/2173 | 28.9 |
| Thiazides | 220/2173 | 10.1 |
| Loop diuretics | 161/2173 | 7.4 |
| α‐Blockers | 69/2173 | 3.2 |
| Calcium channel blockers | 495/2173 | 22.8 |
| β‐Blockers | 1035/2173 | 47.7 |
| ACE inhibitors | 422/2173 | 19.4 |
| Aldosterone antagonists | 14/2173 | 0.6 |
| Lipid‐lowering agents | ||
| None | 1525/2173 | 70.2 |
| Statins | 553/2173 | 25.4 |
| Fibrates | 31/2173 | 1.4 |
| Others | 47/2173 | 2.2 |
Abbreviations: ACE, angiotensin‐converting enzyme; HCTZ, hydrochlorothiazide.